Identification and experimental validation of druggable epigenetic targets in hepatoblastoma

Kahla, 2022, 69 Meyers, 2017, Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children’s Hepatic tumors International Collaboration, Lancet Oncol, 18, 122, 10.1016/S1470-2045(16)30598-8 Wu, 2022, Current approaches in hepatoblastoma-new biological insights to inform therapy, Curr Oncol Rep, 24, 1209, 10.1007/s11912-022-01230-2 Gröbner, 2018, The landscape of genomic alterations across childhood cancers, Nature, 555, 321, 10.1038/nature25480 Zhang, 2021, Molecular mechanisms of hepatoblastoma, Semin Liver Dis, 41, 28, 10.1055/s-0040-1722645 Eichenmüller, 2014, The genomic landscape of hepatoblastoma and their progenies with HCC-like features, J Hepatol, 61, 1312, 10.1016/j.jhep.2014.08.009 Wang, 2021, Patient-derived mutant forms of NFE2L2/NRF2 drive aggressive murine hepatoblastomas, Cell Mol Gastroenterol Hepatol, 12, 199, 10.1016/j.jcmgh.2021.02.004 Cairo, 2008, Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer, Cancer Cell, 14, 471, 10.1016/j.ccr.2008.11.002 Sumazin, 2017, Genomic analysis of hepatoblastoma identifies distinct molecular and prognostic subgroups, Hepatology, 65, 104, 10.1002/hep.28888 Hooks, 2018, New insights into diagnosis and therapeutic options for proliferative hepatoblastoma, Hepatology, 68, 89, 10.1002/hep.29672 Hirsch, 2021, Integrated genomic analysis identifies driver genes and cisplatin-resistant progenitor phenotype in pediatric liver cancer, Cancer Discov, 11, 2524, 10.1158/2159-8290.CD-20-1809 Fernández-Barrena, 2020, Epigenetics in hepatocellular carcinoma development and therapy: the tip of the iceberg, JHEP Rep, 2 Cui, 2016, Genome-wide analysis of DNA methylation in hepatoblastoma tissues, Oncol Lett, 12, 1529, 10.3892/ol.2016.4789 Honda, 2016, Clinical prognostic value of DNA methylation in hepatoblastoma: four novel tumor suppressor candidates, Cancer Sci, 107, 812, 10.1111/cas.12928 Maschietto, 2017, DNA methylation landscape of hepatoblastomas reveals arrest at early stages of liver differentiation and cancer-related alterations, Oncotarget, 8, 10.18632/oncotarget.14208 Carrillo-Reixach, 2020, Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications, J Hepatol, 73, 328, 10.1016/j.jhep.2020.03.025 Sekiguchi, 2020, Integrated multiomics analysis of hepatoblastoma unravels its heterogeneity and provides novel druggable targets, Npj Precis Oncol, 4, 1 Nagae, 2021, Genetic and epigenetic basis of hepatoblastoma diversity, Nat Commun, 12 Beck, 2018, Overexpression of UHRF1 promotes silencing of tumor suppressor genes and predicts outcome in hepatoblastoma, Clin Epigenetics, 10, 27, 10.1186/s13148-018-0462-7 Claveria-Cabello, 2021, Epigenetics in hepatoblastoma, Hepatoma Res, 7, 65 Biswas, 2018, Epigenetic tools (The Writers, the Readers and the Erasers) and their implications in cancer therapy, Eur J Pharmacol, 837, 8, 10.1016/j.ejphar.2018.08.021 Lu, 2020, Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy, Mol Cancer, 19, 10.1186/s12943-020-01197-3 Rivas, 2021, HDAC1-Dependent repression of markers of hepatocytes and P21 is involved in development of pediatric liver cancer, Cell Mol Gastroenterol Hepatol, 12, 1669, 10.1016/j.jcmgh.2021.06.026 Valanejad, 2018, PARP1 activation increases expression of modified tumor suppressors and pathways underlying development of aggressive hepatoblastoma, Commun Biol, 1, 10.1038/s42003-018-0077-8 Burgess, 2015, Age-related changes in MicroRNA expression and pharmacogenes in human liver, Clin Pharmacol Ther, 98, 205, 10.1002/cpt.145 Ranganathan, 2016, Loss of EGFR-ASAP1 signaling in metastatic and unresectable hepatoblastoma, Sci Rep, 6, 10.1038/srep38347 Wagner, 2020, SP8 promotes an aggressive phenotype in hepatoblastoma via FGF8 activation, Cancers (Basel), 12, 1, 10.3390/cancers12082294 Bondoc, 2021, Identification of distinct tumor cell populations and key genetic mechanisms through single cell sequencing in hepatoblastoma, Commun Biol, 4, 10.1038/s42003-021-02562-8 Rivas, 2021, DNA methylation as a key epigenetic player for hepatoblastoma characterization, Clin Res Hepatol Gastroenterol, 45 Yan, 2022, MBD3 promotes hepatocellular carcinoma progression and metastasis through negative regulation of tumour suppressor TFPI2, Br J Cancer, 127, 612, 10.1038/s41416-022-01831-5 Wu, 2021, Protein arginine methylation: from enigmatic functions to therapeutic targeting, Nat Rev Drug Discov, 20, 509, 10.1038/s41573-021-00159-8 Bárcena-Varela, 2019, Dual targeting of histone methyltransferase G9a and DNA-methyltransferase 1 for the treatment of experimental hepatocellular carcinoma, Hepatology, 69, 587, 10.1002/hep.30168 Taylor-Papadimitriou, 2022, Histone methylases and demethylases regulating antagonistic methyl marks: changes occurring in cancer, Cells, 11 Zhang, 2022, Discovery of SIRT7 inhibitor as new therapeutic options against liver cancer, Front Cell Dev Biol, 9, 10.3389/fcell.2021.813233 Bayo, 2019, A comprehensive study of epigenetic alterations in hepatocellular carcinoma identifies potential therapeutic targets, J Hepatol, 71, 10.1016/j.jhep.2019.03.007 Mardinian, 2021, SMARCA4: implications of an altered chromatin-remodeling gene for cancer development and therapy, Mol Cancer Ther, 20, 2341, 10.1158/1535-7163.MCT-21-0433 San José-Enériz, 2017, Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies, Nat Commun, 8, 10.1038/ncomms15424 Nicolle, 2016, Patient-derived mouse xenografts from pediatric liver cancer predict tumor recurrence and advise clinical management, Hepatology, 64, 1121, 10.1002/hep.28621 Du, 2015, DNA methylation pathways and their crosstalk with histone methylation, Nat Rev Mol Cell Biol, 16, 519, 10.1038/nrm4043 Sidhu, 2017, UHRF1: the key regulator of epigenetics and molecular target for cancer therapeutics, Tumour Biol, 39, 1, 10.1177/1010428317692205 Poulard, 2021, Structure, activity, and function of the protein lysine methyltransferase G9a, Life, 11, 1082, 10.3390/life11101082 Tao, 2014, Activation of β-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice, Gastroenterology, 147, 690, 10.1053/j.gastro.2014.05.004 Ding, 2020, Metabolic pathway analyses identify proline biosynthesis pathway as a promoter of liver tumorigenesis, J Hepatol, 72, 725, 10.1016/j.jhep.2019.10.026 Dong, 2020, Regulation of cancer cell metabolism: oncogenic MYC in the driver’s seat, Signal Transduct Target Ther, 5 Pathria, 2021, Harnessing the Co-vulnerabilities of amino acid-restricted cancers, Cell Metab, 33, 9, 10.1016/j.cmet.2020.12.009 Yi, 2021, Ribosomal protein S6: a potential therapeutic target against cancer?, Int J Mol Sci, 23, 10.3390/ijms23010048 Islam, 2018, Autophagic regulation of p62 is critical for cancer therapy, Int J Mol Sci, 19, 10.3390/ijms19051405 Donna, 2016, Coordinated activities of multiple myc-dependent and myc-independent biosynthetic pathways in hepatoblastoma, J Biol Chem, 291, 26241, 10.1074/jbc.M116.754218 Wortel, 2017, Surviving stress: modulation of ATF4-mediated stress responses in normal and malignant cells, Trends Endocrinol Metab, 28, 794, 10.1016/j.tem.2017.07.003 Tameire, 2019, ATF4 couples MYC-dependent translational activity to bioenergetic demands during tumour progression, Nat Cell Biol, 21, 889, 10.1038/s41556-019-0347-9 Zhao, 2016, KDM4C and ATF4 cooperate in transcriptional control of amino acid metabolism, Cell Rep, 14, 506, 10.1016/j.celrep.2015.12.053 van der Mijn, 2022, Transcriptional and metabolic remodeling in clear cell renal cell carcinoma caused by ATF4 activation and the integrated stress response (ISR), Mol Carcinog, 61, 851, 10.1002/mc.23437 Hsiao, 2001, A compendium of gene expression in normal human tissues, Physiol Genomics, 7, 97, 10.1152/physiolgenomics.00040.2001 Lee, 2017, General paucity of genomic alteration and low tumor mutation burden in refractory and metastatic hepatoblastoma: comprehensive genomic profiling study, Hum Pathol, 70, 84, 10.1016/j.humpath.2017.10.007 Hoshida, 2008, Gene expression in fixed tissues and outcome in hepatocellular carcinoma, N Engl J Med, 359, 1995, 10.1056/NEJMoa0804525 Comerford, 2016, Hepatoblastoma modeling in mice places Nrf2 within a cancer field established by mutant β-catenin, JCI Insight, 1, 10.1172/jci.insight.88549 Colyn, 2021, Dual targeting of G9a and DNA methyltransferase-1 for the treatment of experimental cholangiocarcinoma, Hepatology, 73, 2380, 10.1002/hep.31642 Liu, 2017, Histone methyltransferase G9a drives chemotherapy resistance by regulating the glutamate-cysteine ligase catalytic subunit in head and neck squamous cell carcinoma, Mol Cancer Ther, 16, 1421, 10.1158/1535-7163.MCT-16-0567-T Tu, 2018, MYC interacts with the G9a histone methyltransferase to drive transcriptional repression and tumorigenesis, Cancer Cell, 34, 579, 10.1016/j.ccell.2018.09.001 de Smedt, 2021, G9a/GLP targeting in MM promotes autophagy-associated apoptosis and boosts proteasome inhibitor-mediated cell death, Blood Adv, 5, 2325, 10.1182/bloodadvances.2020003217